Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force - 21/11/24
Doi : 10.14283/jpad.2019.12
Serge Gauthier 1, ⁎ 
, J. Alam 2, H. Fillit 3, T. Iwatsubo 4, H. Liu-Seifert 5, M. Sabbagh 6, S. Salloway 7, C. Sampaio 8, J.R. Sims 5, B. Sperling 9, R. Sperling 10, K.A. Welsh-Bohmer 11, J. Touchon 12, 13, B. Vellas 14, P. Aisen 15
, J. Alam 2, H. Fillit 3, T. Iwatsubo 4, H. Liu-Seifert 5, M. Sabbagh 6, S. Salloway 7, C. Sampaio 8, J.R. Sims 5, B. Sperling 9, R. Sperling 10, K.A. Welsh-Bohmer 11, J. Touchon 12, 13, B. Vellas 14, P. Aisen 15EU/US/CTAD Task Force
1 McGill Center for Studies in Aging, Verdun, QC, Canada
2 EIP Pharma Inc., Cambridge, MA, USA
3 The Alzheimer’s Drug Discovery Foundation, New York, NY, USA
4 University of Tokyo, Tokyo, Japan
5 Eli Lilly and Company, Indianapolis, IN, USA
6 L Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
7 The Warren Alpert Medical School of Brown University, Providence, RI, USA
8 CHDI Foundation, Princeton, NJ, USA
9 Lundbeck, Valby, 2500, Copenhagen, Denmark
10 Brigham and Women’s Hospital, Boston, MA, USA
11 Duke University, Durham, NC, USA
12 University Hospital of Montpellier, 34025, Montpellier Cedex 5, France
13 INSERM 1061, Montpellier, France
14 Gerontopole, INSERM U1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France
15 Alzheimer’s Therapeutic Research Institute (ATRI), Keck School of Medicine, University of Southern California, San Diego, CA, USA
a serge.gauthier@mcgill.ca
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.
Le texte complet de cet article est disponible en PDF.Key words : Alzheimer’s disease, amyloid, tau, therapeutics, trial design
Plan
| EU/US/CTAD TASK FORCE: Bjorn Aaris Gronning (Valby); Paul Aisen (San Diego); John Alam (Cambridge); Sandrine Andrieu (Toulouse), Randall Bateman (St. Louis); Monika Baudler (Basel); Joanne Bell (Wilmington); Kaj Blennow (Mölndal); Claudine Brisard (Blue Bell); Samantha Budd-Haeberlein (USA); Szofia Bullain (Basel); Marc Cantillon (Princeton); Maria Carrillo (Chicago); Gemma Clark (Princeton); Jeffrey Cummings (Las Vegas); Daniel Di Giusto (Basel); Rachelle Doody (Basel); Sanjay Dubé (Aliso Viejo); Michael Egan (North Wales); Howard Fillit (New York); Adam Fleisher (Philadelphia); Mark Forman (North Wales); Cecilia Gabriel-Gracia (Suresnes); Serge Gauthier (Verdun); Jeffrey Harris (South San Francisco); Suzanne Hendrix (Salt Lake City); Dave Henley (Titusville); David Hewitt (Blue Bell); Mads Hvenekilde (Basel); Takeshi Iwatsubo (Tokyo); Keith Johnson (Boston); Michael Keeley (South San Francisco); Gene Kinney (South San Francisco); Ricky Kurzman (Woodcliffe Lake); Valérie Legrand (Nanterre); Stefan Lind (Valby); Hong Liu-Seifert (Indianapolis); Simon Lovestone (Oxford); Johan Luthman (Woodcliffe); Annette Merdes (Munich); David Michelson (Cambridge); Mark Mintun (Philadelphia); José Luis Molinuevo (Barcelona); Susanne Ostrowitzki (South San Francisco); Anton Porsteinsson (Rochester); Martin Rabe (Woodcliffe Lake); Rema Raman (San Diego); Elena Ratti (Cambridge); Larisa Reyderman (Woodcliffe Lake); Gary Romano (Titusville); Ivana Rubino (Cambridge); Marwan Noel Sabbagh (Las Vegas); Stephen Salloway (Providence); Cristina Sampaio (Princeton); Rachel Schindler (USA); Peter Schüler (Langen); Dennis Selkoe (Boston); Eric Siemers (New York); John Sims (Indianapolis); Heather Snyder (Chicago); Georgina Spence (Galashiels); Bjorn Sperling (Valby); Reisa Sperling (Boston); Andrew Stephens (Berlin); Joyce Suhy (Newark); Gilles Tamagnan (New Haven); Edmond Teng (South San Francisco); Gary Tong (Valby); Jan Torleif Pedersen (Valby); Jacques Touchon (Montpellier); Bruno Vellas (Toulouse); Vissia Viglietta (Cambridge); Christian Von Hehn (Cambridge); Philipp Von Rosenstiel (Cambridge); Michael Weiner (San Francisco); Kathleen Welsh-Bohmer (Durham); Iris Wiesel (Basel); Haichen Yang (North Wales); Wagner Zago (South San Francisco); Beyhan Zaim (Woodcliffe Lake); Henrik Zetterberg (Mölndal) |
© 2019
THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 6 - N° 3
P. 164-168 - juillet 2019 Retour au numéro
Article précédent
- Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force
- Jeffrey Cummings, K. Blennow, K. Johnson, M. Keeley, R.J. Bateman, J.L. Molinuevo, J. Touchon, P. Aisen, B. Vellas, EU/US/CTAD Task Force
- Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report
- Randall J. Bateman, K. Blennow, R. Doody, S. Hendrix, S. Lovestone, S. Salloway, R. Schindler, M. Weiner, H. Zetterberg, P. Aisen, B. Vellas, EU/US CTAD Task Force
Bienvenue sur EM-consulte, la référence des professionnels de santé.